Skip to main content

Agena Bioscience, Dian Diagnostics Ink Deal Targeting China

NEW YORK (360Dx) – Agena Bioscience today announced an agreement with Chinese medical laboratory firm Zhejian Dian Diagnostics to commercialize Agena's MassArray system and DNA testing applications and products in China.

Financial and other terms of the deal were not disclosed.

Dian has selected the MassArray system as its platform of choice for molecular genetic testing, Agena said in a statement. Based in Hangzhou, China, Dian offers services ranging from third-party diagnostic testing to centralized procurement service of instruments and reagents for hospitals establishing their own laboratories.

"With their extensive network of laboratories and expertise in bringing up new diagnostic tests, [Dian is] an important partner and will further spur the growth of our technology in China," Agena CEO Peter Dansky said in a statement.  

The deal is the most recent by Agena in China as it looks to build its business by targeting the Chinese market. In March, the company reached a deal with Simcere Diagnostics to develop and market companion diagnostics and pharmacogenomics tests. In February 2016, Agena partnered with DaRui Biotechnology to develop in vitro diagnostic tests for cancer and inherited diseases for the Chinese market.